1
1
0
0
Hashtag
#DrugEvidence25
Advertisement · 728 × 90
ICYMI:
3 pearls for Peripheral edema from the TI's Dr. Jessica Otte @drotte.medsky.social
#DrugEvidence25 #edema #MedEd
5
3
0
0
3
2
0
0
😍Speaking now:
The TI's Dr. Jessica Otte @drotte.medsky.social
"Drugs and peripheral edema: a not-so-'swell' side effect"
#DrugEvidence25 #MedEd #CME #edema #prescribing
2
0
0
0
3
2
0
0
1
1
0
0
🚨Speaking now:
Dr. Iliana Lega:
"Evidence-based approaches to menopause: Overcoming misinformation"
#DrugEvidence25 #menopause #MedEd #CME
1
1
0
0
Dr. Aaron Tejani: What are #PrescribingPortraits?
More on Prescribing Portraits here:
www.ti.ubc.ca/portrait/
#DrugEvidence25
0
0
0
0
🚨Now presenting: the TI's Dr. Aaron Tejani
Therapeutics Initiative Prescribing Portraits for BC clinicians
To sign up for Prescribing Portraits:
www.ti.ubc.ca/portrait/
#DrugEvidence25 #MedEd #BetterPrescribing
1
1
0
0
🚨Speaking now: Dr. Colin Dormuth (TI Co-Director)
Overlooked challenges in comparing treatment benefits & harms in randomized trials
#DrugEvidence25
1
1
0
0
🚨Speaking now: Dr. Colin Dormuth (TI Co-Director)
Overlooked challenges in comparing treatment benefits & harms in randomized trials
✅Clarify role of relative/absolute measures of efficacy
✅Explain how typical interpretations of adverse event data provide false sense of security #DrugEvidence25
0
0
0
0
🚨Our TI Annual Course returns for day 2!
ti.ubc.ca/annual-cours...
Speaking now: Dr. David Juurlink (keynote)
"Treating pain is harder than it looks"
#DrugEvidence25 #pain #opioids #chronicpain #NSAIDs
1
1
0
0
🚨Our TI Annual Course returns for day 2!
ti.ubc.ca/annual-cours...
Speaking now: Dr. David Juurlink (keynote)
"Treating pain is harder than it looks"
#DrugEvidence25 #CME #MedEd #pain #opioids #chronicpain
2
0
0
0
TI Annual Course
ti.ubc.ca/annual-cours...
Speaking now: Dr. Jamie Falk
"Heart attack hacks: Translating evidence into everyday care"
#DrugEvidence25 #CME #MedEd #CVD
1
0
0
0
TI Annual Course
ti.ubc.ca/annual-cours...
Speaking now: Dr. Aaron Tejani
"One of these things is a lot like the other. Is the use of enantiomers versus racemic drugs rational in BC?"
#DrugEvidence25 #CME #MedEd
0
0
0
0
TI Annual Course
ti.ubc.ca/annual-cours...
Speaking now: Dr. Guillaume Grenet
"Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in type 2 diabetes"
👎 LOW evidence for primary CVD prevention
#DrugEvidence25 #CME #MedEd #T2DM #diabetes #GLP1
1
1
0
0
TI Annual Course
ti.ubc.ca/annual-cours...
Speaking now: Dr. Guillaume Grenet
"Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in type 2 diabetes"
👎 LOW evidence for primary CVD prevention
#DrugEvidence25 #CME #MedEd #T2DM #diabetes #GLP1
2
2
0
0
TI Annual Course
ti.ubc.ca/annual-cours...
Speaking now: Dr. Guillaume Grenet
"Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in type 2 diabetes"
#DrugEvidence25 #CME #MedEd #T2DM #diabetes #GLP1
0
0
0
0
Dr. Allyson Harrison on #ADHD:
How many professionals apply ALL five DSM-5 criteria before diagnosising ADHD? 🤔
#DrugEvidence25 #MedEd #CME
1
1
0
0
🎺 Our TI Annual Course is underway!
ti.ubc.ca/annual-cours...
Speaking now: Dr. Allyson G. Harrison
"ADHD & other disability diagnoses"
✅ ID common errors in disability assessments
✅ Apply evidence-based assessment practices
✅ Critically evaluate diagnostic conclusions
#DrugEvidence25 #ADHD
0
0
0
0
⌛️ One more sleep until our TI #BestEvidence for Clinicians virtual course starts! ⌛️
ti.ubc.ca/drugevidence25
✅ highly interactive 👥
✅ engaging expert speakers 🧑🏽💻
✅ common + new 💊 tx issues
✅ independent + evidence-based 💯
✅ broad, practical scope 🩺
#CME #MedEd #DrugEvidence25
1
0
0
0
🚨Bringing Best Evidence to Clinicians, our TI annual course, is now FULLY SUBSCRIBED!
New registrants will be added to the wait list and offered a spot if someone cancels: ti.ubc.ca/annual-cours...
#DrugEvidence25 #BetterPrescribing #BetterHealth #MedEd
3
2
0
0
🧵 Register now for our Annual Course, offered virtually this year: ti.ubc.ca/annual-cours...
1/ Featuring expert speakers including @amtejani.bsky.social
"Highlights from TI Portrait"
#DrugEvidence25 #MedEd #CME
1
0
1
0
Learning Objectives:
✅ Provide an overview of #menopause + factors contributing to myths/misinformation
✅ Summarize current evidence on effective treatments + clinical approaches to care
✅ Discuss approaches to individualizing care based on patient needs and risk profiles
#DrugEvidence25
0
0
0
0
🧵 Register now for our Annual Course, offered virtually this year: ti.ubc.ca/annual-cours...
1/ Featuring expert speakers including Dr. Iliana Lega
"Evidence-based approaches to #menopause: Overcoming #misinformation"
#DrugEvidence25 #MedEd #CME
1
1
1
0
2/ Objectives:
✅ Understand how racemic drugs & single-enantiomer versions compare in real clinical outcomes by reviewing RCT evidence
✅ Critically evaluate manufacturer claims about superiority of single-enantiomer 💊 in light of study quality, risk of bias, pt-important outcomes
#DrugEvidence25
1
1
0
0
🧵 Register now for our Annual Course, offered virtually this year: ti.ubc.ca/annual-cours...
1/ Featuring expert speakers including Dr. Aaron Tejani @amtejani.bsky.social
"One of these things is a lot like the other. Is the use of enantiomers versus racemic drugs rational in BC?"
#DrugEvidence25
2
1
1
0
2/ This presentation summarizes the evidence about GLP-1 RA and SGLT2i for CVD prevention in type 2 diabetes.
Learning Objective:
To communicate the uncertainty around the cardiovascular effect of GLP-1 RA
#DrugEvidence25 #MedEd #CME
1
0
0
0
🧵 Don't delay, spaces are filling quickly. Register now for our TI Annual Course: ti.ubc.ca/annual-cours...
1/ Featuring expert speakers including Dr. Guillaume Grenet:
"Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in type 2 diabetes"
#DrugEvidence25
1
0
1
0
2/ Learning objectives:
✅ Evaluate recent clinical trials on post-MI care
✅ Apply evidence-based strategies to guide decisions on intensifying, maintaining, or de-escalating therapy for individual post-MI patients in primary care considering likelihood of long-term benefits/harms
#DrugEvidence25
1
0
0
0